A Phase I Randomised, Double-Blind, Placebo-Controlled Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Oral NP202 in Adult Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2016
At a glance
- Drugs NP 202 (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Sponsors NeuProtect
- 11 Jun 2015 Status changed from recruiting to completed as per Australian New Zealand Clinical Trials Registry record..
- 25 Jul 2014 Status changed from not yet recruiting to recruiting, as per Australian New Zealand Clinical Trials Registry record.
- 15 May 2014 New trial record